Living Cell Technologies Ltd. (AU:1AI)
ASX:1AI
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$28.18M
Enterprise ValueAU$26.27M
Total Cash (Recent Filing)AU$1.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,761,032,200
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtThe company’s lack of debt materially lowers financing costs and bankruptcy risk, preserving financial flexibility. For a development-stage biotech, no interest burden extends runway between fundraises, reduces fixed cash obligations, and improves negotiating leverage with partners or acquirers over the medium term.
Improving Loss TrendReported net losses narrowing year-over-year implies management is improving cost control or achieving milestone-driven progress. A sustained narrowing trend lowers future financing needs, increases credibility with investors and partners, and raises the probability of reaching operational breakeven within a multi-quarter timeframe.
Reduced Cash BurnOperating cash outflows declined in the most recent year versus the prior period, signaling better cash efficiency. Durable reductions in cash burn extend runway, provide more time to advance clinical programs or secure partnerships, and reduce near-term dilution pressure if the trend persists.
Bears Say
Lack Of RevenueEffectively zero commercial revenue means the business remains dependent on external financing, grants, or partnerships to fund R&D and operations. This structural absence of recurring income increases execution risk, makes planning sensitive to capital markets access, and elevates dilution risk over the medium term.
Chronic Cash BurnPersistent negative operating and free cash flow in every reported year reflects structural cash burn. Continued outflows require repeated financing events, constrain long-term planning, and increase the likelihood of equity dilution or unfavorable financing terms absent a clear path to commercial revenues or major licensing deals.
Eroding Balance SheetDeclining equity and shrinking asset bases indicate cumulative losses that erode financial buffers. A weakened balance sheet reduces the company's ability to fund trials, absorb setbacks or attract non-dilutive partners, heightening refinancing risk and limiting strategic optionality over the medium term.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$28.18M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 150 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Mar 04, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 1,761,032,200 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:1AI Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
Technical Analysis
Invex Therapeutics Ltd.
―
Regeneus Ltd.
―
Chimeric Therapeutics Ltd.
―
Neuroscientific Biopharmaceuticals Ltd.
―
Memphasys Ltd
―